NeuroBo Pharmaceuticals Inc
Performance History
| Key Stats | |
|---|---|
| Open | $0.43 |
| Prev. Close | $0.43 |
| EPS | -5.48 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 9, 2023 |
| Dividend Yield % | - |
| Market Cap | $17.38M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 0.43 | 0.45 |
| 52 Week Range | 0.36 | 2.33 |
| Ratios | |
|---|---|
| P/B Ratio | 0.77 |
| Revenue | - |
| Operating M. % | 0.00% |
| Earnings | -$11.83M |
| Earnings Growth % | - |
| EBITDA Margin % | - |
| ROE % | -86.09% |
| EPS | -5.48 |
Score Breakdown
All Score (36 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| NRBO | Market | |
|---|---|---|
| Value | 69 | 42 |
| Quality | 33 | 46 |
| Ownership | 15 | 39 |
| Growth | 15 | 44 |
| Dividends | - | 32 |
All Score (36 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About NeuroBo Pharmaceuticals Inc (NRBO)
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Hyung-Heon Kim
- Headquarters
- Boston
- Employees
- 2
Keep an eye on NeuroBo Pharmaceuticals Inc
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.